Free Float 74,47 %
Shares Float 33,87 M
Shares Outstanding 45,48 M
Genexine, Inc.
Share · KR7095700001 (XKOS)
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of Genexine, Inc.
No Price
Closing Price XKOS 29.04.2026:
5.600,00 KRW
29.04.2026 06:30
Current Prices from Genexine, Inc.
| Exchange | Ticker | Currency | Last Trade | Price | Daily Change |
|---|---|---|---|---|---|
 KOSDAQ |
095700.KQ
|
KRW
|
29.04.2026 06:30
|
5.600,00 KRW
| -110,00 KRW
-1,93 %
|
Share Float & Liquidity
Invested Funds
The following funds have invested in Genexine, Inc.:
Fund | Vol. in million 155,56 | Percentage (%) 0,15 % |
Fund | Vol. in million 54,43 | Percentage (%) 0,02 % |
Fund | Vol. in million 275,54 | Percentage (%) 0,02 % |
Company Profile for Genexine, Inc. Share
Genexine, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of immunotherapeutics and long-acting biologics in South Korea. It develops hyFc platform, a proprietary technology designed to drive the discovery of various differentiated agonistic protein therapeutics; and the Immune Enhancing Technology, a therapeutic DNA vaccine technology. The company's product pipeline includes GX-H9, which is in Phase II clinical trials for the treatment of adult and pediatric growth hormone deficiency; GX-E2, which is in Phase II clinical trials for the treatment of induced anemia; GX-G3, which is in Phase II clinical trials to treat neutropenia; and GX-G6 that is in Phase I clinical trials for the treatment of diabetes. It is also developing GX-188E that is in Phase II clinical trials in combination with KEYTRUDA for the treatment of cervical cancer. Genexine, Inc. has a co-development partnership with Binex Co. Ltd. to develop COVID-19 vaccine. The company was formerly known as Genexine Co., Ltd. and changed its name to Genexine, Inc. in March 2013. Genexine, Inc. was founded in 1999 and is based in Seongnam, South Korea.
Company Data
Name Genexine, Inc.
Company Genexine, Inc.
Website
https://www.genexine.com
Primary Exchange
KOSDAQ
KOSDAQ
ISIN KR7095700001
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Jungwon Woo
Market Capitalization 260 Mrd.
Country South Korea
Currency KRW
Employees 0,1 T
Address Korea Bio Park Building B, 13488 Seongnam
IPO Date 2009-09-15
Dividends from 'Genexine, Inc.'
| Ex-Date | Dividend per Share |
|---|---|
| 15.03.2022 | 0,40 KRW |
Stock Splits
| Date | Split |
|---|---|
| 11.01.2023 | 13:10 |
| 09.11.2022 | 107:100 |
Ticker Symbols
| Name | Symbol |
|---|---|
| KOSDAQ | 095700.KQ |
More Shares
Investors who hold Genexine, Inc. also have the following shares in their portfolio:
